

#### **Medication Assisted Treatment (MAT) Procedure**

Effective Date Revised Date	05/02/20 05/02/20	705007755407	na Yoshioka Ÿoshioka, DSW, MBA, LCSW, Director
Purpose -	To provide Department of Behavioral Health (DBH) staff with instruction in the proper procedures for administering Medication Assisted Treatment (MAT) services.		
MAT Screening Process for New Clients via SARC	client contacts the Screening, Assessment and Referral Center (SARC) reque MAT services:		
JANC	Step		Action
	1	<ul> <li>SARC staff:</li> <li>Follows current busi and:</li> </ul>	ness practice as stated in the SARC manual,
		If services for MAT are deemed	Then
		Appropriate	Complete a warm handoff to the clinic to ensure the client receives an intake appointment.
		Not appropriate	No referral is made for MAT services.
	2	DBH Clinic staff:	
		<ul> <li>by DEA regulation</li> <li>Phone number, in</li> <li>Date of Birth (DC)</li> <li>Medi-Cal Number</li> <li>and</li> <li>Social Security No</li> <li>Schedules two (2) bits</li> <li>Intake appointment</li> <li>the MAT for Subts</li> <li>Office Assistant</li> </ul>	ference (in-person or telehealth as permitted ons), f available, DB), er, known as the Client Index Number (CIN), Number (SSN). ack-to-back appointments for client: ent for review of program paperwork, including stance Use Disorder (SUD) Brochure, with
	3	Clients, Office Assistants (C	DA), and Physicians complete all required forms
		during the intake appointme <u>Note</u> : Refer to <i>Required Fo</i>	ent. rms block for more information.

MAT Screening	Step		Action	
Process for	4	Physicians:		
New Clients			client to determine if criteria for MAT is met;	
via SARC, continued		Complete comprehensive history and physical assessment;		
continueu		Refer the c		
		<ul> <li>A facilit</li> </ul>	y where the appropriate FDA-approved medications	
		are ava	ilable if MAT is accepted, or	
	<ul> <li>The appropriate level of care if MAT is rejected;</li> </ul>			
		<ul> <li>Administer drug treatments, and</li> <li>Document notes in the client's Electronic Health Record (EHR).</li> </ul>		
		Note: Refer to the	Referral Process for MAT Medication block for more	
			ng MAT medication referrals.	
-				
	<b>-</b>			
Referrals for MAT			e process when a referral for MAT services is received	
		following sources:		
		ospitals; irect DBH SUD Clin	ic contact:	
		reatment court;		
		orrectional facility, c	r	
		other programs		
	Step		Action	
	1	DBH Clinic staff:		
		Determines if the client is a new or existing client, and:		
		If the client is	Then	
		New	Schedules the intake appointment with the	
			physician.	
			<u>Note</u> : Please review the MAT Screening Process for	
			New Clients Via Referrals block of this section for more information.	
		An existing		
		client	<ul><li>Refer the client directly to the program, and</li><li>Continue with Step 1.</li></ul>	
		<ul> <li>Confirms th</li> </ul>		
			ment preference (in-person or telehealth);	
			number, if applicable;	
		o DOB;		
			al Number (CIN), and	
		∘ SSN.	the diant two (2) had to had an eighter	
			the client two (2) back-to-back appointments:	
			appointment to review program paperwork, including the r SUDs Brochure, with OA or Medical Services Support	
		Staff, a	••	
	1	-	ysician for comprehensive history and physical	
		assessi	• • • • • •	
	L			

<b>Referrals for</b>	Step	Action
MAT, continued	2	Clients, OAs, and Physicians complete required forms during the intake appointment.
		<b><u>Note</u>:</b> Refer to <i>Required Forms</i> block for more information.
	3	<ul> <li>Physicians:         <ul> <li>Assess the client to determine if criteria for MAT is met,</li> <li>Complete comprehensive history and physical assessment,</li> <li>Refer the client to:                 <ul> <li>A facility where the appropriate FDA-approved medications are available if MAT is accepted, or</li> <li>The appropriate level of care if MAT is rejected;</li> <li>Administer drug treatments, and</li> <li>Document notes in the EHR.</li> </ul> </li> </ul> </li> <li>Note: Refer to the <i>Referral Process for MAT Medication</i> block for more information regarding MAT medication referrals.</li> </ul>

MAT Screening Process for	The table below describes the MAT screening process when an existing client participating in services at a DBH SUD clinic requires MAT services:			
	Step	Action		
Existing DBH SUD Clients	1	<ul> <li>OA schedules an appointment with a physician under the client's existing episode.</li> </ul>		
	2	<ul> <li>Clinic staff:</li> <li>Confirms the client's:</li> </ul>		
		<ul> <li>Appointment preference (in-person or telehealth),</li> <li>Phone number, if applicable,</li> </ul>		
		■ DOB,		
		<ul> <li>Medi-Cal Number (CIN),</li> <li>SSN.</li> </ul>		
		<ul> <li>Schedules the client two (2) back-to-back appointments:         <ul> <li>Intake appointment for review of program paperwork, including the MAT for SUDs Brochure, with OA or Medical Services Support Staff, and</li> </ul> </li> </ul>		
		<ul> <li>The comprehensive history and physical assessment with the physician.</li> </ul>		
	3	<ul> <li>Clients, OAs, and Physicians complete required forms during the intake appointment.</li> </ul>		
		<b>Note:</b> Refer to <i>Required Forms</i> block for more information.		

MAT	Step			Action
Screening Process for Existing DBH SUD Clients, continued	4	<ul> <li>Physicians: <ul> <li>Assess the client to determine if criteria for MAT is met;</li> <li>Complete comprehensive history and physical assessment;</li> <li>Refer the client to: <ul> <li>A facility where the appropriate FDA-approved medications are available if MAT is accepted, or</li> <li>The appropriate level of care if MAT is rejected;</li> </ul> </li> <li>Administer drug treatments, and</li> <li>Document notes in the EHR.</li> </ul> </li> <li><u>Note</u>: Refer to the <i>Referral Process for MAT Medication</i> block for more information regarding MAT medication referrals and the <i>Comprehensive history and physical assessment</i> block for more information regarding the comprehensive history and physical assessment.</li> </ul>		
Comprehensive History and				e appointment, a follow-up appointment is an. The physician will:
Physical Assessment	Step Action			
	1	Sub web • Assess th	ostance Use osite or in the ne client to d on provided	nt with the Medication Assisted Treatment for Disorders brochure, available on the DBH e SUDRS clinics, with information regarding MAT, letermine if they meet the criteria for MAT using by comprehensive history and physical
		If the client	Then the p	physician will
		Meets	Ask the clie	ent if they agree to begin MAT, and:
		criteria	If the client	Then the physician will
			Agrees	<ul> <li>Prescribe and review appropriate MAT medications, including the benefits and risks, and</li> <li>Go to Step 2 below</li> </ul>
			Does not agree	<ul> <li>Refer the client to:         <ul> <li>The appropriate level of care,</li> <li>Community resources,</li> <li>Mental health services, or</li> <li>Physical health services;</li> </ul> </li> <li>Document the client's refusal of MAT and where the client was referred.</li> </ul>

Comprehensive	Step	Action	
History and Physical Assessment,	1, cont	If the client	Then the physician will
Continued		Does not meet criteria	Refer the client to the appropriate level of care.
	2	Monitor and ac	dminister treatment via follow-up appointments.
			physician must ensure the client has sufficient medication able until the scheduled follow-up appointment.
			the <i>Follow-up appointments</i> block for more information w-up appointments.
	3		following in the Electronic Health Record (EHR):
			iate needs;
		<ul> <li>Substance use history;</li> </ul>	
		<ul> <li>Past surgical history;</li> </ul>	
		Psychiatric history;	
			l history;
			ition record;
		•	history;
		Allergie	
		Diagno	
		<ul> <li>Progress notes;</li> <li>Informed consent for MAT modality;</li> </ul>	
			Status Exam/Physical Examination;
			l of MAT services, if applicable, and
		• Statem	ent of Medical necessity.

Comprehensiv e History and Physical Assessment,	Clients who request opioid use disorder treatment, such as methadone must be referred to an NTP clinic via the Substance Use Disorder Referral Form (SUDRS034) within 24 hours of request. The NTP clinic will prescribe, manage, and monitor the
Continued	medications. Medical staff determines if the appropriate FDA-approved medications are available in the NTP facility, and:

If the FDA-approved medications are	Then the clinical staff will			
Available	Prescribe the appro	Prescribe the appropriate medication.		
Not available,Refer the client to the nearest NTP f medications are available, and Ask the client if they need transporta		ailable, and		
	If the client	Then clinical staff will		
	Needs	Provide the client with		
	transportation	transportation assistance, as		
		indicated and according to		
		available resources, and		
		document the actions taken.		
	Does not need	Document the client does not		
	transportation,	need transportation.		

**Notes:** A list of NTP Facility Locations can be found on the DBH website.

No-Show for Intake Appointment	<ul> <li>When a client fails to keep a scheduled intake appointment, staff must:</li> <li>Attempt to contact client to: Discuss the missed appointment with the client, and reschedule, and</li> <li>Document the discussion and any action taken under the client's initial contact section in the electronic health record.</li> </ul>
Follow-up Appointments	<ul> <li>Clients must be scheduled follow-up appointments when clients are approved for medications to ensure the medications are properly administered. When a client fails to keep a scheduled follow-up appointment, staff must: <ul> <li>Attempt to contact client to:</li> <li>Discuss the missed appointment with the client, and reschedule, and</li> </ul> </li> <li>Document the discussion and any action taken in the client's case file.</li> </ul>
	Continued on next page

Medications	Medications	Benefits	Risks
	Acamprosate	<ul> <li>Reduces:         <ul> <li>Cravings for alcohol, and</li> <li>Alcohol consumption</li> </ul> </li> <li>Taken as a pill three times per day.</li> </ul>	<ul> <li>Should NOT be used if severe kidney problems are present;</li> <li>Depression;</li> <li>Insomnia;</li> <li>Diarrhea;</li> <li>Anxiety, and/or</li> <li>Suicidal thoughts.</li> </ul>
	Buprenorphine	<ul> <li>Effective for opioid withdrawal;</li> <li>Manages cravings and withdrawal symptoms, and</li> <li>May be used when pain is also a problem.</li> </ul>	<ul> <li>Constipation;</li> <li>Physical Dependence;</li> <li>Slow or shallow breathing;</li> <li>Sedation;</li> <li>Precipitated Withdrawal;</li> <li>Nausea/vomiting;</li> <li>Fatigue;</li> <li>Vertigo;</li> <li>Increased sweating;</li> <li>Headache;</li> <li>Lowered hormone secretion;</li> <li>Dental Cavities;</li> <li>Swelling of the legs, and/or</li> <li>Liver Problems</li> </ul>
	Disulfiram	Reduces cravings	<ul> <li>Strong interaction with alcohol;</li> <li>Nausea or vomiting;</li> <li>Headaches;</li> <li>Sweating;</li> <li>Chest pain;</li> <li>Trouble breathing;</li> <li>Blurred vision;</li> <li>Garlic like taste;</li> <li>Liver Problems, and/or</li> <li>Death</li> </ul>

Benefits and	Medications	Benefits	Risks
Risks of Medications, continued	Naloxone	<ul> <li>Reverses an overdose by blocking the effects of opioids, and</li> <li>Restores normal breathing in opioid overdoses</li> </ul>	<ul> <li>Withdrawal;</li> <li>Agitation;</li> <li>Increased blood pressure;</li> <li>Rebound respiratory depression, and/or</li> <li>May require multiple doses.</li> <li>Effectiveness limited to opioid overdose</li> </ul>
	Naltrexone	<ul> <li>Reduces rewarding effects and cravings of alcohol;</li> <li>Should NOT be used when pain is also a problem, and</li> <li>Taken as a once daily pill.</li> </ul>	<ul> <li>Nausea;</li> <li>Headache;</li> <li>Liver Problems;</li> <li>Depression;</li> <li>Suicidal Thoughts;</li> <li>Opioid Withdrawal, and/or</li> <li>Should NOT be taken with opioid medications.</li> </ul>
	Long-acting injectable naltrexone	<ul> <li>Reduces rewarding effects and cravings of alcohol;</li> <li>Administered as a once monthly injection, and</li> <li>Should NOT be used when pain is also a problem.</li> </ul>	<ul> <li>Should NOT be used if severe kidney problems are present;</li> <li>Depression;</li> <li>Insomnia;</li> <li>Diarrhea;</li> <li>Anxiety, and/or</li> <li>Suicidal thoughts.</li> </ul>
	Long-acting injectable buprenorphine	<ul> <li>Reduces withdrawal symptoms and cravings, and</li> <li>Administered as a once monthly injection.</li> </ul>	<ul> <li>Nausea;</li> <li>Headache;</li> <li>Constipation;</li> <li>Fatigue;</li> <li>Insomnia;</li> <li>Precipitated withdrawal;</li> <li>Injection site reaction;</li> <li>Physical Dependence;</li> <li>Slow or shallow breathing;</li> <li>Sedation;</li> <li>Liver Problems;</li> <li>Lowered hormone secretion, and/or</li> <li>Death.</li> </ul>

Required intake forms	The table below describes the forms completed by the client, OA/Medical Services Support Staff and physician at the intake appointment:		
	Completed by	Forms	
	Client	Registration Questionnaire;	
		Notice of Personal Rights (SUDRS003);	
		Advance Health Care Directive (COM018);	
		Notice of Privacy Practices (NOPP) and	
		Acknowledgement of Receipt of NOPP (COM004);	
		Request for Restriction of Confidential	
		Communication (COM030), and	
		Health Questionnaire (DHCS5103)	
	OA/Medical	Tuberculosis (TB) Questionnaire (ADS005);	
	Services	<ul> <li>Client Payment Agreement (CLP001);</li> </ul>	
	Support Staff	Client Admission Agreement (Avatar) (SUDRS022);	
		<ul> <li>Consent for Outpatient Treatment (COM013);</li> </ul>	
		Title 22 Fair hearing Rights (SUDRS002);	
		Program rules;	
		Authorization to Release Protected Health	
		Information (PHI) (COM001), if applicable, and	
		Drug Medi-Cal Organized Delivery System (DMC-	
	Dhumining	ODS) Handbook Summary and Report	
	Physician	Medication Consent Form;	
		Opioid Agreement for Buprenorphine Medication	
		Assisted Treatment (SUDRS040);	
		Women's Health Questionnaire;	
		Diagnosis Form;     Drablem List;	
		Problem List;     Boviour and Sign Health Questionnairs (DHCS5102)	
		<ul> <li>Review and Sign Health Questionnaire (DHCS5103), and</li> </ul>	
		• Review and Sign the TB Questionnaire (ADS005).	
		<ul> <li><u>Note</u>: The SUDRS040 form is optional and at the</li> <li>discretion of the physician.</li> </ul>	

#### **MAT training** Training on MAT policy and procedure and benefits and risks of all FDAapproved medications for all facility staff must be:

- Completed at the following times:
  - Upon hire for all facility staff,
  - o Quarterly, and
  - As needed;
- Conducted by a qualified trainer, who is trained and monitored by the Medical Director;
- Provided through the RELIAS online platform, and
- Documented in the employee's personnel file.

Referenced Forms, Policies, and Procedures	<ul> <li>DBH Standard Practice Manual and Departmental Forms: <ul> <li>Control, Access and Accountability of Medications and Medical Supplies Policy (MDS2008)</li> <li>Control, Access and Accountability of Medications and Medical Supplies Procedure (MDS2008-1)</li> <li>Medication Disposal Procedure (MDS2023)</li> <li>Advance Health Care Directive (COM018)</li> <li>Notice of Privacy Practices (NOPP) and Acknowledgement of Receipt of NOPP (COM004)</li> <li>Request for Restriction of Confidential Communication (COM030)</li> <li>Notice of Personal Rights (SUDRS003)</li> <li>Substance Use Disorder Referral Form (SUDRS034)</li> <li>Tuberculosis (TB) Questionnaire (ADS005)</li> <li>Client Payment Agreement (CLP001)</li> <li>Client Admission Agreement (Avatar) (SUDRS022)</li> <li>Authorization to Release Protected Health Information (PHI) (COM001)</li> <li>Consent for Outpatient Treatment (COM013)</li> <li>Title 22 Fair hearing Rights (SUDRS002),</li> <li>Opioid Agreement for Buprenorphine Medication Assisted Treatment (SUDRS040)</li> </ul> </li> <li>DBH Website <ul> <li>Medication Assisted Treatment for Substance Use Disorders</li> </ul> </li> </ul>
Reference(s)	Title 42 of the Code of Federal Regulations § 8.11(h) Health Questionnaire (DHCS5103) <u>BHIN 23-054</u>